ANDA 90324, held by Pharmobedient. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 90324 (Carbidopa And Levodopa), held by Pharmobedient, was first approved by FDA on Sep 28, 2009, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 2009 | Original application | Approved | None posted |
| Carbidopa And Levodopa10MG;100MG · tablet;oral | Carbidopa; Levodopa | Discontinued |
| Carbidopa And Levodopa25MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;250MG · tablet;oral | Carbidopa; Levodopa | Discontinued |
| Feb 2, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 19, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 19, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 28, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters